NCT02853682

Brief Summary

The glycocalyx is a layer of proteins and complex sugars covering the endothelium of vessels. Its role as capillary filtration control is important. In case of alteration of the glycocalyx, experimental models and some clinical studies show an increased capillary leak responsible for interstitial edema. The analysis of glycocalyx in routine care is important to guide volume expansion. Indeed, the literature provides evidence about the poor prognosis of excess water and its impact on organ. This analysis challenge is to justify filling solution of choice according to the characteristic of this capillary leakage.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
28

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 20, 2016

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 7, 2016

Completed
27 days until next milestone

First Posted

Study publicly available on registry

August 3, 2016

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2018

Completed
Last Updated

August 21, 2018

Status Verified

August 1, 2018

Enrollment Period

2.5 years

First QC Date

July 7, 2016

Last Update Submit

August 20, 2018

Conditions

Keywords

glycocalyxcapillary leak syndrome

Outcome Measures

Primary Outcomes (1)

  • glycocalyx proteins 1

    proteoglycan in patient plasma is assayed.

    48 hours

Study Arms (2)

presence of a vascular dysfunction

plasma

Biological: plasma

absence of vascular dysfunction

plasma

Biological: plasma

Interventions

plasmaBIOLOGICAL

assesment of glycocalyx protein

absence of vascular dysfunctionpresence of a vascular dysfunction

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients going for cardiac surgery enrolled for 48 hours after surgery.

You may qualify if:

  • cardiac surgery

You may not qualify if:

  • auricular fibrillation
  • endocarditis
  • aortic dissection
  • end stage chronic renal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens Picardie

Amiens, 80054, France

Location

Related Publications (3)

  • Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. doi: 10.1016/s0735-1097(01)01746-6.

    PMID: 11788217BACKGROUND
  • Becker BF, Jacob M, Leipert S, Salmon AH, Chappell D. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015 Sep;80(3):389-402. doi: 10.1111/bcp.12629. Epub 2015 May 22.

    PMID: 25778676BACKGROUND
  • Chawla LS, Ince C, Chappell D, Gan TJ, Kellum JA, Mythen M, Shaw AD; ADQI XII Fluids Workgroup. Vascular content, tone, integrity, and haemodynamics for guiding fluid therapy: a conceptual approach. Br J Anaesth. 2014 Nov;113(5):748-55. doi: 10.1093/bja/aeu298. Epub 2014 Sep 17.

    PMID: 25231767BACKGROUND

MeSH Terms

Conditions

Capillary Leak Syndrome

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Osama ABOU ARAB, MD

    CHU Amiens

    PRINCIPAL INVESTIGATOR
  • Emmanuel LORNE, MD-PhD

    CHU Amiens

    STUDY DIRECTOR
  • Pierre-Gregoire GUINOT, MD

    CHU Amiens

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 7, 2016

First Posted

August 3, 2016

Study Start

January 20, 2016

Primary Completion

August 1, 2018

Study Completion

August 1, 2018

Last Updated

August 21, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations